PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA

Similar Items

• Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
  by: Rafiye Ciftciler, et al.
  Published: (2020-05-01)
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  by: Edvan De Queiroz Crusoe, et al.
  Published: (2020-04-01)
• Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
  by: Farzaneh Ashrafi, et al.
  Published: (2020-01-01)
• DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS
  by: EQ Crusoe, et al.
  Published: (2021-10-01)
• PRELIMINARY RESULTS OF DARATUMUMAB, CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIED TREATMENT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TRANSPLANT ELIGIBLE (TE) PATIENTS
  by: E.Q. Crusoé, et al.
  Published: (2020-11-01)